StreetInsider.com News Articles

Erasca, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

Fri, 19 Jun 2026 16:37:00 -0400

New York, New York and New Orleans, Louisiana--(Newsfile Corp. - June 19, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Erasca, Inc. ("Erasca" or the "Company") (NASDAQ: ERAS) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of investors of Erasca, Inc. who were adversely affected if they purchased the Company's shares between January 14, 2025 and April 26, 2026, both dates inclusive (the "Class Period"). This action is pending in the United States District Court for

Erasca, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

Fri, 19 Jun 2026 16:37:00 -0400

Erasca, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

Thu, 18 Jun 2026 16:36:00 -0400

New York, New York and New Orleans, Louisiana--(Newsfile Corp. - June 18, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Erasca, Inc. ("Erasca" or the "Company") (NASDAQ: ERAS) of a class action securities lawsuit.

Erasca, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

Thu, 18 Jun 2026 16:36:00 -0400

Erasca, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

Wed, 17 Jun 2026 16:31:00 -0400

New York, New York and New Orleans, Louisiana--(Newsfile Corp. - June 17, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Erasca, Inc. ("Erasca" or the "Company") (NASDAQ: ERAS) of a class action securities lawsuit.

Erasca, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

Wed, 17 Jun 2026 16:31:00 -0400

Form 144 Erasca, Inc. Filed by: Erasca Foundation

Mon, 15 Jun 2026 17:53:00 -0400

si-local-file:///var/storage/secattach/20260615/26648831.html

Form 144 Erasca, Inc. Filed by: Erasca Foundation

Mon, 15 Jun 2026 17:53:00 -0400

si-local-file:///var/storage/secattach/20260615/26648831.html

BofA Securities Upgrades Erasca Inc (ERAS) to Neutral, 'we see the downside case as now less compelling'

Thu, 04 Jun 2026 05:13:29 -0400

(Updated - June 4, 2026 5:13 AM EDT)

BofA Securities analyst Alec Stranahan upgraded Erasca Inc (NASDAQ: ERAS) from Underperform to Neutral with a price target of $16.00 (from $9.00).

The analyst comments "We are moving to Neutral (from Underperform), with the debate now shifting from whether ERAS-0015 works to whether it can matter commercially. Early pan-RAS activity appears real, KOL feedback has been constructive, and the share move in our view now better reflects known risks. ERAS-4001 adds a second shot on goal 2H26e and could be an upside driver if a broader therapeutic window is realized. M&A also remains a

BofA Securities Upgrades Erasca Inc (ERAS) to Neutral, 'we see the downside case as now less compelling'

Thu, 04 Jun 2026 05:13:29 -0400

(Updated - June 4, 2026 5:13 AM EDT)

BofA Securities analyst Alec Stranahan upgraded Erasca Inc (NASDAQ: ERAS) from Underperform to Neutral with a price target of $16.00 (from $9.00).

BofA Securities Upgrades Erasca Inc (ERAS) to Neutral, 'we see the downside case as now less compelling'

Thu, 04 Jun 2026 05:13:29 -0400

(Updated - June 4, 2026 5:13 AM EDT)

BofA Securities analyst Alec Stranahan upgraded Erasca Inc (NASDAQ: ERAS) from Underperform to Neutral with a price target of $16.00 (from $9.00).

BofA Securities Upgrades Erasca Inc (ERAS) to Neutral, 'we see the downside case as now less compelling'

Thu, 04 Jun 2026 05:13:29 -0400

(Updated - June 4, 2026 5:13 AM EDT)

BofA Securities analyst Alec Stranahan upgraded Erasca Inc (NASDAQ: ERAS) from Underperform to Neutral with a price target of $16.00 (from $9.00).

Erasca to Present at the Jefferies Global Healthcare Conference

Wed, 27 May 2026 08:00:00 -0400

SAN DIEGO, May 27, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Jefferies Global Healthcare Conference being held at the Marriott Marquis in New York, NY. Management will participate in a fireside chat on Wednesday, June 3, 2026, at 3:10 pm Eastern Time and will also participate in one-on-one investor meetings.